Cargando…

A panel of blood lipids associated with cognitive performance, brain atrophy, and Alzheimer's diagnosis: A longitudinal study of elders without dementia

INTRODUCTION: We sought lipid‐metabolic biomarkers involved in the processes underlying cognitive decline and detected them in association with Alzheimer's disease (AD) phenotypes. METHODS: A least absolute shrinkage and selection operator logistic regression model was used to select lipids tha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Ya‐Hui, Shen, Xue‐Ning, Xu, Wei, Huang, Yu‐Yuan, Li, Hong‐Qi, Tan, Lin, Tan, Chen‐Chen, Dong, Qiang, Tan, Lan, Yu, Jin‐Tai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Blood‐based Biomarkers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7507431/ https://www.ncbi.nlm.nih.gov/pubmed/32995461 http://dx.doi.org/10.1002/dad2.12041

Ejemplares similares

Plasma amyloid, tau, and neurodegeneration biomarker profiles predict Alzheimer's disease pathology and clinical progression in older adults without dementia
por: Shen, Xue‐Ning, et al.
Publicado: (2020)

Differential diagnostic performance of a panel of plasma biomarkers for different types of dementia
por: Thijssen, Elisabeth H., et al.
Publicado: (2022)

Plasma clusterin levels and risk of dementia, Alzheimer's disease, and stroke
por: Weinstein, Galit, et al.
Publicado: (2016)

Reduced plasma desmosterol-to-cholesterol ratio and longitudinal cognitive decline in Alzheimer's disease
por: Sato, Yoshiaki, et al.
Publicado: (2015)

Cerebrospinal fluid and serum MHPG improve Alzheimer's disease versus dementia with Lewy bodies differential diagnosis
por: Janssens, Jana, et al.
Publicado: (2018)

MCP-1 and eotaxin-1 selectively and negatively associate with memory in MCI and Alzheimer's disease dementia phenotypes
por: Bettcher, Brianne M., et al.
Publicado: (2016)

Nutrients required for phospholipid synthesis are lower in blood and cerebrospinal fluid in mild cognitive impairment and Alzheimer's disease dementia
por: van Wijk, Nick, et al.
Publicado: (2017)

The diagnostic performance of neurofilament light chain in CSF and blood for Alzheimer's disease, frontotemporal dementia, and amyotrophic lateral sclerosis: A systematic review and meta-analysis
por: Forgrave, Lauren M., et al.
Publicado: (2019)

Altered levels of blood proteins in Alzheimer's disease longitudinal study: Results from Australian Imaging Biomarkers Lifestyle Study of Ageing cohort
por: Gupta, Veer Bala, et al.
Publicado: (2017)

Effect of APOE ε4 allele on levels of apolipoproteins E, J, and D, and redox signature in circulating extracellular vesicles from cognitively impaired with no dementia participants converted to Alzheimer's disease
por: Ben Khedher, Mohamed Raâfet, et al.
Publicado: (2021)

Apolipoproteins and Alzheimer's pathophysiology
por: Koch, Manja, et al.
Publicado: (2018)

Differential blood DNA methylation across Lewy body dementias
por: Nasamran, Chanond A., et al.
Publicado: (2021)

Molecular markers of neuropsychological functioning and Alzheimer's disease
por: Edwards, Melissa, et al.
Publicado: (2015)

A blood screening test for Alzheimer's disease
por: O'Bryant, Sid E., et al.
Publicado: (2016)

Blood-based metabolic signatures in Alzheimer's disease
por: de Leeuw, Francisca A., et al.
Publicado: (2017)

Blood DNA methylation signatures to detect dementia prior to overt clinical symptoms
por: Fransquet, Peter Daniel, et al.
Publicado: (2020)

MicroRNA deregulation and chemotaxis and phagocytosis impairment in Alzheimer's disease
por: Guedes, Joana R., et al.
Publicado: (2015)

Lipoprotein-associated phospholipase A2, homocysteine, and Alzheimer's disease
por: Doody, Rachelle S., et al.
Publicado: (2015)

Deep learning shows no morphological abnormalities in neutrophils in Alzheimer's disease
por: Chabrun, Floris, et al.
Publicado: (2021)

Plasma microRNA vary in association with the progression of Alzheimer's disease
por: Guévremont, Diane, et al.
Publicado: (2022)

Plasma phospholipids and prevalence of mild cognitive impairment and/or dementia in the ARIC Neurocognitive Study (ARIC-NCS)
por: Li, Danni, et al.
Publicado: (2016)

Blood-based protein predictors of dementia severity as measured by δ: Replication across biofluids and cohorts
por: Royall, Donald R., et al.
Publicado: (2019)

Plasma sphingolipid changes with autopsy-confirmed Lewy body or Alzheimer's pathology
por: Savica, Rodolfo, et al.
Publicado: (2016)

Crosswalk study on blood collection‐tube types for Alzheimer's disease biomarkers
por: Jonaitis, Erin M., et al.
Publicado: (2022)

Prediction of conversion from mild cognitive impairment to dementia with neuronally derived blood exosome protein profile
por: Winston, Charisse N., et al.
Publicado: (2016)

A novel detection method of cleaved plasma high-molecular-weight kininogen reveals its correlation with Alzheimer's pathology and cognitive impairment
por: Yamamoto-Imoto, Hitomi, et al.
Publicado: (2018)

Alterations of membrane protein expression in red blood cells of Alzheimer's disease patients
por: Várady, György, et al.
Publicado: (2015)

Utility of plasma neurofilament light and total tau for clinical trials in Alzheimer's disease
por: Raket, Lars Lau, et al.
Publicado: (2020)

The global Alzheimer's Association round robin study on plasma amyloid β methods
por: Pannee, Josef, et al.
Publicado: (2021)

Prospective associations of plasma phospholipids and mild cognitive impairment/dementia among African Americans in the ARIC Neurocognitive Study
por: Li, Danni, et al.
Publicado: (2016)

Stability of blood-based biomarkers of Alzheimer's disease over multiple freeze-thaw cycles
por: Keshavan, Ashvini, et al.
Publicado: (2018)

Effects of pre‐analytical procedures on blood biomarkers for Alzheimer's pathophysiology, glial activation, and neurodegeneration
por: Ashton, Nicholas J., et al.
Publicado: (2021)

Comparing biological markers of Alzheimer's disease across blood fraction and platforms: Comparing apples to oranges
por: O'Bryant, Sid E., et al.
Publicado: (2015)

Detection of Alzheimer's disease at mild cognitive impairment and disease progression using autoantibodies as blood-based biomarkers
por: DeMarshall, Cassandra A., et al.
Publicado: (2016)

The ratio of phosphatidylcholines to lysophosphatidylcholines in plasma differentiates healthy controls from patients with Alzheimer's disease and mild cognitive impairment
por: Klavins, Kristaps, et al.
Publicado: (2015)

Plasma apolipoprotein J as a potential biomarker for Alzheimer's disease: Australian Imaging, Biomarkers and Lifestyle study of aging
por: Gupta, Veer Bala, et al.
Publicado: (2015)

LDL cholesterol and uridine levels in blood are potential nutritional biomarkers for clinical progression in Alzheimer's disease: The NUDAD project
por: de Leeuw, Francisca A., et al.
Publicado: (2020)

Objective subtle cognitive decline and plasma phosphorylated tau181: Early markers of Alzheimer's disease‐related declines
por: Thomas, Kelsey R., et al.
Publicado: (2021)

Aβ misfolding in blood plasma measured by immuno‐infrared‐sensor as an age‐independent risk marker of Alzheimer's disease
por: Möllers, Tobias, et al.
Publicado: (2021)

Elevated plasma neurofilament light in aging reflects brain white‐matter alterations but does not predict cognitive decline or Alzheimer's disease
por: Nyberg, Lars, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_nb22ktf8eoetnshhi94lf482t4